Preparation for infectious inflammatory diseases treatment and/or prevention

FIELD: pharmacology.

SUBSTANCE: invention relates to an antiseptic preparation in the form of a gel that contains chlorhexidine gluconate-0.01-0.5 g, methyl-4-hydroxybenzoate-0.01-0.1 g, ethyl 4-hydroxybenzoate-0.01-0.1 g, propyl-4-hydroxybenzoate-0.01-0.1 g, propylene glycol 5-70 g, hydroxyethylcellulose – 1.5-5 g and water - up to 100 g.

EFFECT: creation of a new drug that is effective against pathogens that cause sexually transmitted diseases and is not toxic and irritating.

3 cl, 8 ex, 2 tbl

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention represents a method for early postoperative treatment of chronic rhinosinusitis involves a pre-anemisation of a nasal mucosa with an adrenalin solution, a decrustation involves by the fact that the decrustation is followed by administering the preparation 'Argogel' 1.0 ml 2 times a day for 10 minutes throughout 2 weeks.

EFFECT: reducing the length of treatment by fast elimination of the clinical manifestations of the inflammation, as well as maintaining a stable remission, expanding the range of drugs applicable in otorhinolaryngology.

4 dwg, 2 ex

FIELD: biotechnology.

SUBSTANCE: increase in biocidal and immunobiological action due to the use of distilled water ionised with silver ions and adding into the composition of succinic, ascorbic, citric acid and aethonium.

EFFECT: increase in biocidal immunobiological properties of the antiseptic-stimulant of Dorogov ASD-2F.

6 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: two-duct drain tube is intraoperatively inserted into a residual cavity. The tube is delivered onto an anterior abdominal wall. The cyst cavity is irrigated with 0.05% chlorhexidine every day from the second postoperative day that is followed by administering the preparation of 10% povidone iodine with the drain tube pinched for 3-5 minutes. The procedure is performed until the cyst cavity is eliminated completely.

EFFECT: method provides the reliable treatment of the residual cyst cavity following marsupialisation and open echinococcectomy, as well as prevents the postoperative complications by achieving the aseptic inflammation of the inner surface of the fibrous capsule surface followed by the cyst cavity obliteration.

2 dwg, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a new hydrate of 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol hydrochloride salt in the crystalline form with the characteristics below. The hydrate can be used for producing a drug or for treating or preventing a transplanted organ or tissue rejection, or autoimmune diseases in a therapeutically effective amount. The above hydrate is characterised by an X-ray powder diffractogram having peaks at approximately 2.9, 17.2, 30.6, 28.2, 24.4, 8.6 and 25.9 degrees 2-Theta with a limit of error of ±0.2 degrees for each value of 2θ, having a purity of 90% or more, and containing 5.2 to 5.9% of water.

EFFECT: invention also characterises a pharmaceutical composition with using the above hydrate.

4 cl, 4 dwg, 8 tbl, 14 ex

FIELD: medicine.

SUBSTANCE: invention can be used for the local treatment of trophic ulcers, infected and persistent septic wounds, degrees I-II-IIIA burns, traumatic skin injuries, pyoinflammatory skin diseases, bed sores, etc. The invention refers to a preparation, which contains a streptocide powder 1-2.5 g, Ichthyol ointment 7-10 g and castol oil 87.5-92 ml.

EFFECT: reducing the length of treatment up to 14 days with no side effects.

4 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to veterinary and veterinary obstetrics, and can be applied for the treatment of clinical mastitis in cows. For this purpose after evening milking for 4 days, parts of the udder with signs of mastitis are influenced with an alternating magnetic field from the magnetic-therapeutic apparatus AMnp-02 "Solnyshko". The duration of exposure constitutes 10 minutes. Mastoxidine, heated to 40°C, in a dose of 20 ml three days successively, is additionally intracisternally introduced for 3 days running.

EFFECT: method ensures an increase of the treatment efficiency due to the enforcement of mastoxidine action at deep cellular and intra-cellular levels with the acceleration of its penetration in tissues.

1 dwg, 2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: therapeutic agent contains hypromellose, boric acid and a consistency base; it additionally contains anesthesin or lidocaine as an analgesic in an amount of 0.00001-0.5 g.

EFFECT: fixing a lubricating agent on the catheter enabling preventing mucosal injuries accompanying a drainage procedure, and eliminating side effects.

3 cl, 6 ex

FIELD: veterinary medicine.

SUBSTANCE: preparation for treatment of infected wounds in the toe region of animals, containing dimethyl sulphoxide, methyl cellulose, additionally comprises tylosin tartrate, sulphadimine, trimethoprim in the following ratio of components, wt %: tylosin tartrate - 2-3, sulphadimine - 4-5, trimethoprim - 1-1.5, dimethyl sulphoxide - 10-15, methylcellulose - 3.0-3.5, water - the rest. The claimed method comprises applying the claimed preparation without preliminary wound cleaning. The preparation is applied to the wound with the layer thickness of 2-3 mm, without application of soft dressing. The treated animals are kept for 2-3 hours on the dry surface.

EFFECT: use of claimed group of inventions increases the efficiency of treatment.

4 cl, 7 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, and concerns a pharmaceutical composition for treating gastroduodenal ulcer in the form of tablets, capsules or gel, containing therapeutic agents and a consistency base applicable for each dosage, wherein the therapeutic agents are as follows: recombinant interferon specified in a group: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma; antiseptics; amino acids specified in a group: arginine, histidine, lysine, cysteine, methionine, glutamic acid; and antioxidants specified in a group: beta-carotene, vitamin C, vitamin E.

EFFECT: invention has the integrated body effect promoting faster healing of the mucosal defect accompanying the aggravated gastroduodenal ulcer and preventing recurrences, including by the eradication effect.

6 cl, 5 ex

FIELD: veterinary medicine.

SUBSTANCE: pharmaceutical composition in the form of ointments for treatment of mastitis in cows comprises n-tetradecyltributylphosphonium bromide as active ingredient and petrolatum as an excipient at the ratio of 1:2000.

EFFECT: invention provides a pharmaceutical composition in the form of an ointment, which is new in mechanism of action, effective when applied topically at low therapeutic concentration.

2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel choline salt of 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid, corresponding to formula and to its crystalline form. Crystalline form of salt (A) has characteristic peaks at diffraction angles (2θ(E)) 7.1, 11.5, 19.4, 20.3, 21.5, 22.0, 22.6, 23.5 and 26.2 in diagram of powder diffraction of X-rays, characteristic peaks of values of chemical shifts (δ(ppm)) 155.8, 149.8, 145.3, 118.0, 113.7, 111.6, 110.3, 98.1, 69.8, 58.7, 57.1 and 55.5 in solid-state 13C NMR spectrum and characteristic peaks of values of chemical shifts (δ(ppm)) -131.6, -145, and -151.8 in solid-state 19F NMR spectrum, as well as endothermic peak about 213°C in diagram of differential-thermal analysis.

EFFECT: compound has excellent solubility and stability in storage.

5 cl, 5 dwg, 3 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, gynaecology, birth control techniques used as and when necessary, and emergency contraception. Ulipristal acetate or its metabolite is administered orally in a female no more than 72 hours to 120 hours after a sexual encounter in a dose of 20 to 30 mg. Another dose can be administered again at least twice a month. The preparation can be administered either in the form of an immediate-release dosage form, in the form of a tablet.

EFFECT: method provides the high efficacy of emergency contraception even in low doses and late administration of the preparation - up to 120 hours after the sexual encounter as compared to a reference preparation of levonorgestrel.

7 cl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to dermatology, and can be used for selecting a therapeutic approach to acne in females by examining biological fluids and prescribing preparations depending on the clinical findings. The biological fluids are blood and urine; blood serum hormones and steroid urine profile are tested, and the derived values are compared to the standard norms specific for the absence of acne, while the preparations are prescribed according to the comparison results. Specifically, if observing an increase of blood luteinising hormone up to 16 mIU/ml, testosterone up to 4 ng/ml, an increase of urine androsterone up to 20 mcmole/24 hours, etiocholanolone up to 11 mcmole/24 hours, total 17-ketosteroids up to 35 mcmole/24 hours, van de Calseyde's discriminant up to 3, the combined oral contraceptive Jess with the anti-androgenic effect. If also observing an increase of immunoreactive protein up to 12.90 mcUnit/ml and insulin-line growth factor 1 up to 361.04 ng/ml, the combined oral contraceptive Jess and Metformine or Metformine are prescribed. If observing a decrease of blood oestradiol up to 140 pmole/l or an increase of the concentration of luteinising hormone up to 7 mIU/ml, dihydroepiandrosterone sulphate up to 4 mmole/l, 17 - hydroxyprogesterone up to 4 nmole/l and testosterone up to 4 nmole/l in blood and an increase of urine androsterone up to 17 mcmole/24 hours, etiocholanolone up to 17 mcmole/24 hours, 11 - ketoandrosterone up to 2.5 mcmole/24 hours, 11 - ketoetiocholanolone up to 2.5 mcmole/24 hours, 17 - ketosteroids up to 50 mcmole/24 hours and van de Calseyde's discriminant up to 3, the glucocorticoid Metypred is prescribed. The high blood concentration of luteinising hormone up to 15 mIU/ml, dihydroepiandrosterone sulphate up to 6.82 mcmole/l, 17 - hydroxyprogesterone up to 4 nmole/l and an increase of urine androsterone up to 19.5 mcmole/24 hours, etiocholanolone up to 16 mcmole/24 hours, dihydroepiandrosterone up to 7 mcmole/24 hours, 17 - ketosteroids up to 45 mcmole/24 hours and van de Calseyde's discriminant up to 3.5 enables using the combined oral contraceptive Jess and the glucocorticoid Metypred. And the preparation Dostinex is prescribed in observing the above values in a combination with an increase of blood prolactin up to 750 IU/ml and a decrease of blood oestradiol up to 95.48 pcg/ml.

EFFECT: method enables providing higher therapeutic selectivity and clinical effectiveness in acne without the need of thorough examination to be conducted.

4 ex

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine. System of medication delivery includes, at least, one compartment, which contains loaded with medicinal substance heart-shaped layer from thermoplastic polymer, loaded with medicinal substance intermediate layer from thermoplastic polymer and non-containing medicinal substances coating from thermoplastic polymer, which covers intermediate layer. Heart-shaped layer is loaded with crystals of first compound, in particular with pharmaceutically active compound. Intermediate layer is loaded with crystals of second compound, in particular with pharmaceutically active compound. Both active compounds are loaded over their corresponding concentration of saturation. Described is method of contraception, application of delivery system for application in contraception or hormone-substituting therapy, application of system for production of contraception set and method of producing three-layer system of medication delivery.

EFFECT: ensuring independent speed of release of active compounds.

15 cl, 7 ex, 8 tbl, 26 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: pharmaceutical composition contains as a first active agent, 6β, 7β; 15β, 16β-dimethylenene-oxo-17α-pregn-4-ene-21,17-carbolactone (drospirenone) in an amount according to a daily dose after the administration of the composition and making approximately 2 to approximately 4 mg, and as a second active agent, 17a-ethinylestradiol (ethinylestradiol) in an amount according to a daily dose and making approximately 0.01 mg to approximately 0.05 mg together with one or more pharmaceutically acceptable carriers or additives. The composition contains drospirenone applied on inert carrier particles. A method for preparing a pharmaceutical composition involves spraying of the drospirenone and ethinylestradiol solution on the inert carrier particles. The pharmaceutical preparation according to the invention contains a number of separately packed and individually taken daily dosage units of the described compositions in a single package used for oral administration for at least 21 days running with said daily dosage units containing the combination of drospirenone and ethinylestradiol. The composition may additionally contain 7 and less daily dosage units containing no active agent, or containing ethinylestradiol only.

EFFECT: invention provides higher oral bioavailability of drospirenone.

20 cl, 5 dwg, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine, namely pharmacy and may be used for creating an oral solid dosage form. The dosage form contains a pharmaceutically acceptable salt of an alkaline-earth metal of 5-methyk-(6S)-tetrahydrofolic acid and granules containing progestogen, oestrogen and microcrystalline cellulose. What is also presented is a pharmaceutical kit for females for providing the concentrations or treating the diseases, conditions or symptoms associated with endogenous oestrogen deficiency.

EFFECT: group of inventions provides the good storage stability of tetrahydrofolic acid, and at the same time provides rapid and reliable release of oestrogen and progestogen being parts of the composition.

13 cl, 3 dwg, 4 tbl, 6 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a diacetate of racemic 18-ethyl-gona-1,3,5(10),8(9)-tetraene-3,17β-diol, having anti-implantation and antioxidant activity with low uterotropic action. Presence of antioxidant activity in said steroid is essential since compounds with such action can be agents for preventing oestrogen-dependent breast cancer.

EFFECT: compounds exhibit anti-implantation and antioxidant activity with low uterotropic action, which is an advantage over agents used in practice.

1 cl, 1 ex, 4 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: as a first active agent a pharmaceutical composition contains drospirenone in the amount equal to a daily dose when administering the composition and making 2 to 4 mg, and as a second active agent - ethinylestradiol in the amount equal to a daily dose and making 0.01 mg to 0.05 mg, together with one or more pharmaceutically acceptable carriers or additives. Drospirenone as a part of the pharmaceutical composition has a particle surface area more than 10000 cm2/g. Preferentially, drospirenone is fine-grained or sprayed from a drospirenone solution by inert carrier particles. The preparation contains a number of separately packed and individually taken daily dosage units in a single package used for oral administration for at least 21 days running with said daily dosage units containing a combination of drospirenone and ethinylestradiol. The preparation may additionally contain 7 and less daily dosage units containing no active agent, or containing ethinylestradiol only.

EFFECT: combination of drospirenone and ethinylestradiol provides reliable contraceptive activity ensured by the use of a maximum dose of drospirenone which causes no side effects, particularly, excess diuresis.

29 cl, 5 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry and relates in particular to medication for women, which has contraceptive and protective action against inflectional diseases: herpes, HIV infections, viral disease. Medication for vaginal application, possessing contraceptive and protective against inflectional diseases action contains actively-acting components and target base. As actively-acting components medication contains contraceptive, bactericidal, anti-inflammatory preparations, and as target base it contains gel-forming biocompatible polymers and L-lysin hydrochloride with specified component ratio per 1 g. Medication presents gel, ointment, cream, liniment.

EFFECT: medication not only has contraceptive action, but also makes it possible to simultaneously prevent sexually transmitted infection diseases.

3 cl, 6 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely to gynaecology, and can be used for female contraception. Inventions include methods of female contraception. That is ensured by the multiple administration of a dosage form started in a day of month marked either by 'n+3', or 'n+4', or 'n+5', or 'n+6' date and taken out in a day marked by 'n' number of the next month for at least two cycles where 'n' is a date either within 1 to 25, or 1 to 24, or 1 to 23, or 1 to 22 respectively. Also, the inventions involve female contraception kits containing at least two dosage forms and patient information leaflets according to the declared modes of contraception. Besides, the inventions comprise a dosing regimen reminder system adjusted in such a manner that it allows to choose one specific date either within 1 to 25, or within 1 to 24, or within 1 to 23, or within 1 to 22 regardless of a month, as a date when the dosage form is always taken out and a date when a new dosage form shall be used either through three, or through four, or through five, or through six days thereafter respectively.

EFFECT: inventions provide convenient administration of contraceptives with maintained efficacy of contraception and its increase in certain cases.

1 tbl, 9 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel choline salt of 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid, corresponding to formula and to its crystalline form. Crystalline form of salt (A) has characteristic peaks at diffraction angles (2θ(E)) 7.1, 11.5, 19.4, 20.3, 21.5, 22.0, 22.6, 23.5 and 26.2 in diagram of powder diffraction of X-rays, characteristic peaks of values of chemical shifts (δ(ppm)) 155.8, 149.8, 145.3, 118.0, 113.7, 111.6, 110.3, 98.1, 69.8, 58.7, 57.1 and 55.5 in solid-state 13C NMR spectrum and characteristic peaks of values of chemical shifts (δ(ppm)) -131.6, -145, and -151.8 in solid-state 19F NMR spectrum, as well as endothermic peak about 213°C in diagram of differential-thermal analysis.

EFFECT: compound has excellent solubility and stability in storage.

5 cl, 5 dwg, 3 tbl, 8 ex

Up!